Organizing services for cardiovascular prevention
暂无分享,去创建一个
[1] G. Balady,et al. Transforming exercise-based cardiac rehabilitation programs into secondary prevention centers: a national imperative. , 2001, Journal of cardiopulmonary rehabilitation.
[2] I. Ockene,et al. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. , 1997, Circulation.
[3] Daniel W. Jones,et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.
[4] James A. Blumenthal,et al. Cardiac rehabilitation as secondary prevention , 1995 .
[5] Thomas Bodenheimer,et al. Improving primary care for patients with chronic illness. , 2002, JAMA.
[6] M. Pfeffer,et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. , 2006, Circulation.
[7] Kevin Weiss,et al. The Evidence Base for Tight Blood Pressure Control in the Management of Type 2 Diabetes Mellitus , 2003, Annals of Internal Medicine.
[8] R. Greenberg. Overview of patient compliance with medication dosing: a literature review. , 1984, Clinical therapeutics.
[9] Sarah Corley,et al. A Multimethod Quality Improvement Intervention To Improve Preventive Cardiovascular Care , 2004, Annals of Internal Medicine.
[10] S. Grundy,et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Executive Summary Conference Proceeding for Healthcare Professionals From a Special Writing Group of the American Heart Association , 2002, Circulation.
[11] Constance K Haan,et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Circulation.
[12] Rowena J Dolor,et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. , 2007, Journal of the American College of Cardiology.
[13] T. Pearson,et al. Screening family members at high risk for coronary disease. Why isn't it done? , 2001, American journal of preventive medicine.
[14] D. Berry,et al. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. , 2003, Archives of internal medicine.
[15] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[16] S. Ornstein,et al. Quality improvement using electronic medical records: a case study of a high-performing practice. , 2001, Topics in health information management.
[17] J. Blumenthal,et al. Cardiac rehabilitation as secondary prevention. Agency for Health Care Policy and Research and National Heart, Lung, and Blood Institute. , 1995, Clinical practice guideline. Quick reference guide for clinicians.
[18] R. Krauss,et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). , 1994, Circulation.
[19] R. Collins,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.
[20] C. Lenfant. Conquering cardiovascular disease: progress and promise. , 1999, JAMA.
[21] M Hørder,et al. Randomised controlled trial of structured personal care of type 2 diabetes mellitus , 2001, BMJ : British Medical Journal.
[22] R. Haynes,et al. Effects of computer-based clinical decision support systems on physician performance and patient outcomes: a systematic review. , 1998, JAMA.
[23] V. Fuster,et al. Task force #5--the role of cardiovascular specialists as leaders in prevention: from training to champion. 33rd Bethesda Conference. , 2002, Journal of the American College of Cardiology.
[24] G. Balady,et al. Comparison of outcome of cardiac rehabilitation in black women and white women. , 1995, The American journal of cardiology.
[25] J. Mckenney,et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. , 2005, The American journal of cardiology.
[26] S. Smith. Clinical treatment of dyslipidemia: practice patterns and missed opportunities. , 2000, The American journal of cardiology.
[27] S. Connolly,et al. Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. , 1999, Psychosomatic medicine.
[28] C. McDonald. Protocol-based computer reminders, the quality of care and the non-perfectability of man. , 1976, The New England journal of medicine.
[29] Claude Lenfant,et al. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[30] James C. Robinson,et al. External incentives, information technology, and organized processes to improve health care quality for patients with chronic diseases. , 2003, JAMA.
[31] D. B. Friedman,et al. Compliance and efficacy of cardiac rehabilitation and risk factor modification in the medically indigent. , 1997, The American journal of cardiology.
[32] J. Fleg,et al. Secondary Prevention of Coronary Heart Disease in the Elderly (With Emphasis on Patients ≥75 Years of Age): An American Heart Association Scientific Statement From the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention , 2002, Circulation.
[33] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[34] S. Grundy,et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[35] T. Robinson,et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. , 2005, Circulation.
[36] T. Pearson,et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.
[37] Thomas Bodenheimer,et al. Improving primary care for patients with chronic illness: the chronic care model, Part 2. , 2002, JAMA.
[38] James F Sallis,et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.
[39] J S Berg,et al. Medication compliance: a healthcare problem. , 1993, The Annals of pharmacotherapy.
[40] Sankey V. Williams,et al. Evaluation of Primary Care Patients with Chronic Stable Angina: Guidelines from the American College of Physicians , 2004, Annals of Internal Medicine.
[41] T. Pearson. Primer in Preventive Cardiology , 1994 .
[42] E. Benjamin,et al. Discovering the Full Spectrum of Cardiovascular Disease: Minority Health Summit 2003: Report of the Outcomes Writing Group , 2005, Circulation.
[43] M. Smith,et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. , 2002 .
[44] J. Sallis,et al. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. , 2003, Circulation.
[45] D. Sackett,et al. Manipulation of the therapeutic regimen to improve compliance: conceptions and misconceptions. , 1977, Clinical pharmacology and therapeutics.
[46] C. Viscoli,et al. Treatment adherence and risk of death after a myocardial infarction , 1990, The Lancet.
[47] Brian T. Austin,et al. Organizing care for patients with chronic illness. , 1996, The Milbank quarterly.
[48] John Horgan,et al. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. , 2004, Circulation.
[49] Sandeep Vijan,et al. Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians , 2004, Annals of Internal Medicine.
[50] D. Atkins,et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. , 2003, Circulation.
[51] T. Fahey,et al. Interventions to improve adherence to lipid-lowering medication. , 2016, The Cochrane database of systematic reviews.
[52] M. Pfeffer,et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.
[53] C. Feifer,et al. System supports for chronic illness care and their relationship to clinical outcomes. , 2001, Topics in health information management.
[54] D. Bates,et al. Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. , 2003, Archives of internal medicine.
[55] R B Haynes,et al. Interventions to enhance medication adherence. , 2005, The Cochrane database of systematic reviews.
[56] R. Gliklich,et al. Get With the Guidelines for Cardiovascular Secondary Prevention , 2004 .
[57] D. Salem,et al. Prevalence of risk factors in men with premature coronary artery disease. , 1991, The American journal of cardiology.
[58] Christopher P Cannon,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.